Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics (CYTK) has granted equity-based compensation to 6 new employees who joined in February 2025. The package includes 23,337 stock options at an exercise price of $46.16 per share and 15,153 restricted stock units (RSUs).
The RSUs will vest over 3 years with a 40-40-20 schedule: 40% after year one, 40% after year two, and 20% after year three. The stock options will vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next 36 months. The options have a 10-year term.
These grants were made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
Cytokinetics (CYTK) ha concesso una compensazione basata su azioni a 6 nuovi dipendenti che si sono uniti a febbraio 2025. Il pacchetto include 23.337 opzioni su azioni a un prezzo di esercizio di 46,16 $ per azione e 15.153 unità azionarie ristrette (RSU).
Le RSU matureranno in 3 anni secondo un piano 40-40-20: il 40% dopo il primo anno, il 40% dopo il secondo anno e il 20% dopo il terzo anno. Le opzioni su azioni matureranno in 4 anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi 36 mesi. Le opzioni hanno un termine di 10 anni.
Questi conferimenti sono stati effettuati come incentivi materiali all'occupazione ai sensi della Regola di quotazione Nasdaq 5635(c)(4) e sono soggetti al Piano di Incentivazione Azionaria 2004 modificato e ristampato dell'azienda.
Cytokinetics (CYTK) ha otorgado compensación basada en acciones a 6 nuevos empleados que se unieron en febrero de 2025. El paquete incluye 23,337 opciones sobre acciones a un precio de ejercicio de $46.16 por acción y 15,153 unidades de acciones restringidas (RSUs).
Las RSUs se consolidarán durante 3 años con un calendario 40-40-20: 40% después del primer año, 40% después del segundo año y 20% después del tercer año. Las opciones sobre acciones se consolidarán durante 4 años, con el 25% consolidándose después del primer año y el 75% restante consolidándose mensualmente durante los siguientes 36 meses. Las opciones tienen un plazo de 10 años.
Estos otorgamientos se realizaron como incentivos materiales para el empleo bajo la Regla de Cotización de Nasdaq 5635(c)(4) y están sujetos al Plan de Incentivos de Capital Modificado y Restablecido de 2004 de la empresa.
사이토키네틱스 (CYTK)는 2025년 2월에 합류한 6명의 신규 직원에게 주식 기반 보상을 부여했습니다. 패키지에는 23,337개의 스톡 옵션이 포함되어 있으며, 행사가격은 주당 46.16달러이고 15,153개의 제한된 주식 단위 (RSU)가 포함되어 있습니다.
RSU는 3년 동안 40-40-20 일정에 따라 배정됩니다: 첫 해에 40%, 두 번째 해에 40%, 세 번째 해에 20%입니다. 스톡 옵션은 4년 동안 배정되며, 첫 해에 25%가 배정되고 나머지 75%는 다음 36개월 동안 매월 배정됩니다. 옵션은 10년의 유효기간을 가지고 있습니다.
이 보상은 Nasdaq 상장 규정 5635(c)(4) 아래에서 고용에 대한 물질적 유인으로 제공되었으며, 회사의 수정 및 재작성된 2004년 주식 인센티브 계획의 적용을 받습니다.
Cytokinetics (CYTK) a accordé une compensation basée sur des actions à 6 nouveaux employés qui ont rejoint en février 2025. Le paquet comprend 23 337 options d'achat d'actions à un prix d'exercice de 46,16 $ par action et 15 153 unités d'actions restreintes (RSU).
Les RSU seront acquises sur 3 ans selon un calendrier 40-40-20 : 40% après la première année, 40% après la deuxième année et 20% après la troisième année. Les options d'achat d'actions seront acquises sur 4 ans, avec 25% acquises après la première année et les 75% restantes acquises mensuellement au cours des 36 mois suivants. Les options ont une durée de 10 ans.
Ces attributions ont été effectuées en tant qu'incitations matérielles à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4) et sont soumises au Plan d'Incitation en Actions modifié et révisé de 2004 de l'entreprise.
Cytokinetics (CYTK) hat 6 neuen Mitarbeitern, die im Februar 2025 beigetreten sind, eine aktienbasierte Vergütung gewährt. Das Paket umfasst 23.337 Aktienoptionen zu einem Ausübungspreis von 46,16 $ pro Aktie und 15.153 eingeschränkte Aktieneinheiten (RSUs).
Die RSUs werden über 3 Jahre mit einem 40-40-20 Zeitplan fällig: 40% nach dem ersten Jahr, 40% nach dem zweiten Jahr und 20% nach dem dritten Jahr. Die Aktienoptionen werden über 4 Jahre fällig, wobei 25% nach dem ersten Jahr und die verbleibenden 75% monatlich über die nächsten 36 Monate fällig werden. Die Optionen haben eine Laufzeit von 10 Jahren.
Diese Zuwendungen wurden als materielle Anreize für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt und unterliegen dem geänderten und neu gefassten 2004 Equity Incentive Plan des Unternehmens.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 14, 2025 it granted stock options to purchase an aggregate of 23,337 shares of common stock and 15,153 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 6 employees, whose employment commenced in February 2025, as a material inducement to their employment.
The RSUs will vest over 3 years, with
The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About Cytokinetics
Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
